99mTc-HMPAO-labeled liposomes: an investigation into the effects of some formulation factors on labeling efficiency and in vitro stability

Mirahmadi, N.; Babaei, Mohammad Hosein; Vali, A.M.; Daha, Fariba Johari; Kobarfard, Farzad; Dadashzadeh, Simin

doi:10.1016/j.nucmedbio.2007.12.001

Cited by 19 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…99m Tc is an ideal radioisotope for single photon emission computed tomography (SPECT) due to its halflife (6.02 h) and gamma energy (140 keV). Additionally, it is widely employed and the most commonly used radioisotope in both clinical applications of nuclear medicine and pre-clinical studies to determine pharmacokinetic properties of the new drugs in animals [36][37][38]. PL and PL-PLGA were radiolabeled with 99m Tc utilizing tin chloride as reducing agent.…”

Section: Resultsmentioning

confidence: 99%

99mTc labeled plumbagin: estrogen receptor dependent examination against breast cancer cells and comparison with PLGA encapsulated form

Kılçar

Tekin

Müftüler

et al. 2015

J Radioanal Nucl Chem

View full text Add to dashboard Cite

Plant origin products having anticancer properties come into prominence due to widespread of cancer. Plumbagin has various biological activities like anticancer activity. Estrogen receptor (ER) specificity of plumbagin (PL) and radiolabeled PL investigated by in vitro studies on ER? and ER-adenocarcinoma cells. Additionally, PLGA encapsulation was carried out to reduce toxicity of plumbagin and encapsulation effect was investigated. Plumbagin radiolabeled with 100 % in yields and had ER specificity. Furthermore, PLGA encapsulation effected positively on properties of plumbagin; reduced toxicity, increased stability and ER specificity. A promising agent for the diagnosis of ER? breast cancer is suggested.

show abstract

Section: Resultsmentioning

confidence: 99%

99mTc labeled plumbagin: estrogen receptor dependent examination against breast cancer cells and comparison with PLGA encapsulated form

Kılçar

Tekin

Müftüler

et al. 2015

J Radioanal Nucl Chem

View full text Add to dashboard Cite

show abstract

“…The HMPAO kit, which contained 0.5 mg of HMPAO, 7.6 µg of stannous chloride dihydrate, and 4.5 mg of sodium chloride, was kept in a nitrogen atmosphere. HMPAO was produced and distributed by Pars Isotope Co., Tehran, Iran (Mirahmadi et al, 2008). The solution was shaken for at least ten seconds before platelet labeling.…”

Section: Preparation Of 99m Tc-hmpaomentioning

confidence: 99%

99m Technetium-HMPAO-labeled platelet scan in practice: Preparation, quality control, and biodistribution studies

Parvizi

Farzanefar

Khalaj

et al. 2022

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

There is no biodistribution or imaging data on 99m technetium (Tc)-hexamethyl propylamine oxime (HMPAO)-labeled platelets in the literature. The current study aimed to present updated information about the clinical procedures for preparation and use of labeled platelets. Following two-step centrifugation at 1500 and 2500 rpm, the platelets were extracted from whole blood into platelet-rich plasma (PRP) above the buffy coat and then from PRP into a platelet pellet at the bottom of the tube. The 99m Tc-HMPAO-labeled platelets were inspected for purity, viability, release of 99m Tc from platelets, and sterility. Also, microscopic examination and thin layer chromatography (TLC) were performed. Biodistribution was assessed following necropsy in BALB/c mice and through imaging of New Zealand rabbits. The separation ratio was estimated at 98%, and radiochemical purity was measured to be 80%. The labeling efficiency was above 30% in more than half of the assays (range: 17-43%). The release of 99m Tc from platelets was 9% per hour at 37ºC. After 24 hours, stability was estimated at 54% in the human serum. The target organs of mice included the spleen and liver. In rabbits, the imaging results indicated liver as the target organ. Thyroid uptake was negligible up to 90 minutes. Based on the findings, extraction of platelets and labeling them with 99m Tc-HMPAO is a feasible and safe approach in routine practice.

show abstract

“…Preloaded glutathione reduces the complex to a more hydrophilic species that is trapped in the aqueous core and retained in vivo. This labeling approach is highly efficient (85-90% 99m Tc incorporation) and it is not influenced by the size of the liposomes [105], by the lipid composition [106,107], or by the presence of PEG on the liposome surface [108]. Another lipophilic moiety used for after-loading liposome labeling is the SNS/S complex 99m Tc-BMEDA (Fig.…”

Section: Technetium and Rhenium Radiolabelingmentioning

confidence: 99%

Radiolabeled Nanoplatforms: Imaging Hot Bullets Hitting their Target

Rossin

2011

Nanoplatform‐Based Molecular Imaging

View full text Add to dashboard Cite

Nanomedicine is a rapidly evolving field. Every year, new and more sophisticated nanoplatforms (NPs) designed to deliver drugs to specific targets or for molecular imaging of disease states make their appearance on the scientific scene. The assessment of the in vivo distribution of these NPs is the first step in order to fully understand their potential as candidate nanomedicines and to predict and prevent toxic side effects. To this aim, the incorporation of a radionuclide in the NP is of great advantage, as radiometric assays are rapid and quantitative. Furthermore, noninvasive nuclear imaging techniques are highly sensitive, achieve high tissue penetration and good spatial resolution, and can accelerate the translation of new NPs into the clinic. This chapter gives an overview of the strategies to label NPs with a variety of radionuclides (radiometals and radiohalogens), focusing on some of the hurdles that scientists must overcome (or take into consideration) when administering these radioconjugates in vivo. Furthermore, the latest achievements in molecular imaging of angiogenesis with radiolabeled NPs are reviewed.The most recent publications on nanoplatforms labeled with ␥ -and ␤ + -emitting radionuclides for SPECT and PET imaging are reviewed. Different strategies to label nanoplatforms are described, particularly those involving radiometals ( 64 Cu, 111 In, 67/68 Ga, 86 Y, 99m Tc, and 186/188 Re) and radiohalogens ( 123/124/125/131 I, 76 B, and 18 F). Some of the problems occurring when evaluating radiolabeled nanoplatforms in vivo are also covered. Finally, the use of radiolabeled nanoplatforms for angiogenesis imaging with PET and SPECT is discussed.

show abstract

99mTc-HMPAO-labeled liposomes: an investigation into the effects of some formulation factors on labeling efficiency and in vitro stability

Cited by 19 publications

References 8 publications

99mTc labeled plumbagin: estrogen receptor dependent examination against breast cancer cells and comparison with PLGA encapsulated form

99mTc labeled plumbagin: estrogen receptor dependent examination against breast cancer cells and comparison with PLGA encapsulated form

99m Technetium-HMPAO-labeled platelet scan in practice: Preparation, quality control, and biodistribution studies

Radiolabeled Nanoplatforms: Imaging Hot Bullets Hitting their Target

Contact Info

Product

Resources

About